The combination of idronoxil with a novel promising treatment for late-stage prostate cancer [177Lu]Lu-PSMA-targeted radionuclide therapy with is also being explored as part of the LuPIN clinical trial (182–185). The gene discussed is FOLH1; the disease is prostate carcinoma.